Sartorius Stedim Biotech S.A.

WBAG:DIM Stock Report

Market Cap: €18.3b

Sartorius Stedim Biotech Past Earnings Performance

Past criteria checks 1/6

Sartorius Stedim Biotech has been growing earnings at an average annual rate of 5.4%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 13.6% per year. Sartorius Stedim Biotech's return on equity is 4.2%, and it has net margins of 5.9%.

Key information

5.4%

Earnings growth rate

5.3%

EPS growth rate

Life Sciences Industry Growth20.2%
Revenue growth rate13.6%
Return on equity4.2%
Net Margin5.9%
Next Earnings Update28 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sartorius Stedim Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

WBAG:DIM Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,736161641143
30 Jun 242,747170636134
31 Mar 242,716255625129
31 Dec 232,776310618130
30 Sep 232,959460598131
30 Jun 233,170635619132
31 Mar 233,356717604135
31 Dec 223,493876612132
30 Sep 223,381681605125
30 Jun 223,259625577123
31 Mar 223,094559564119
31 Dec 212,887414532111
30 Sep 212,639523479103
30 Jun 212,39346945098
31 Mar 212,14339841789
31 Dec 201,91033639284
30 Sep 201,74329937384
30 Jun 201,60025535381
31 Mar 201,52025433481
31 Dec 191,44123531879
30 Sep 191,39324730868
30 Jun 191,33623830165
31 Mar 191,27422329361
31 Dec 181,21220828361
30 Sep 181,17218527760
30 Jun 181,12117326459
31 Mar 181,09316225957
31 Dec 171,08116125853
30 Sep 171,07315125253
30 Jun 171,08915725550
31 Mar 171,07515725049
31 Dec 161,05215424448
30 Sep 161,00914524247
30 Jun 1697114223446
31 Mar 1692613622643
31 Dec 1588411821742
30 Sep 1585011120743
30 Jun 157818919735
31 Mar 157347618939
31 Dec 146847218434
30 Sep 146467117339
30 Jun 146206716839
31 Mar 146046816538
31 Dec 135886615936

Quality Earnings: DIM has a large one-off gain of €59.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: DIM's current net profit margins (5.9%) are lower than last year (15.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DIM's earnings have grown by 5.4% per year over the past 5 years.

Accelerating Growth: DIM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DIM had negative earnings growth (-65.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.4%).

Return on Equity

High ROE: DIM's Return on Equity (4.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 16:12
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stéphan DubosqArkeon Finance
Charles Pitman-KingBarclays
Scott BardoBerenberg